摘要
多囊卵巢综合征(PCOS)是育龄期妇女常见的生殖内分泌疾病.近年来,胰高血糖素样肽-1(GLP-1)受体激动剂的问世是重要的医学进展,此类药物可以促进胰岛素分泌及胰岛β细胞生长,抑制食欲减缓胃排空,近而降低体质量和改善胰岛素抵抗(IR),同时有调整月经周期、性激素紊乱及提高妊娠率的作用,因此逐渐应用于PCOS的治疗.目前较常使用的药物包括利拉鲁肽(Liraglutide)和艾塞那肽(Exenatide),多项研究证实此类药物无论是单独使用还是和二甲双胍联合应用,都有很好的治疗效果.本文就GLP-1受体激动剂在PCOS中的临床应用作一综述.
Polycystic ovary syndrome(PCOS)is one of the most common reproductive endocrine diseases of women in reproductive age.In recent years,the advent of glucagon like peptide-1(GLP-1)receptor agonists is an important medical progress.Such drugs can promote insulin secretion and islet beta cell growth,inhibit appetite,slow down gastric emptying,reduce weight and improve insulin resistance(IR).What’s more,it can adjust menstrual cycles,sex hormone disorders and increase the pregnancy rate of PCOS patients.As a result,they are gradually applied to the treatment of PCOS.Currently,the most frequent used drugs include liraglutide and exenatide.A number of studies have confirmed there are positively curative effects,both the monotherapy and the combining way with metformin.This article reviews the clinical application of GLP-1 receptor agonists in PCOS.
作者
周启敏
李亚婷
朱荣妍
张学红
Zhou Qimin;Li Yating;Zhu Rongyan;Zhang Xuehong(Gansu Provincial Hospital,Lanzhou 730000,China;The Reproductive Medicine Special Hospital of the 1st Hospital of Lanzhou University,Key Laboratory for Reproductive Medicine and Embryo of Gansu Province,Lanzhou 730000,China)
出处
《中华生殖与避孕杂志》
CAS
CSCD
北大核心
2019年第7期579-585,共7页
Chinese Journal of Reproduction and Contraception
